T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.

Naoya Katsuyama, Yoshiki Akatsuka|PubMed|2023

Cited by 2